Fee Schedule Strategy for Crown & Bridge: What Lab Costs Actually Tell You About Practice Margin

Fee schedule conversations usually happen in the wrong room. A practice owner sits down with a consultant, pulls a regional benchmark, adjusts the codes that feel underpriced, and signs off until the next cycle. The lab invoice never enters the conversation. Neither does the remake log. Neither does the chair-time-per-unit number that quietly defines whether a D2740 is a profitable hour or a break-even one.

This post is for the restorative practice owner or associate who runs 40 to 120 crown-and-bridge units a month and wants the fee schedule to reflect what the case actually costs to deliver. It applies whether you are a solo GP, a prosthodontist running anterior esthetic cases at premium fees, or a small DSO setting one schedule across 12 locations.

The Three Inputs That Should Drive a C&B Fee Review

Forget the regional percentile chart for a minute. The three inputs that matter are:

1. Lab cost per unit, by material and by case complexity.A monolithic posterior zirconia crown and a layered anterior lithium disilicate are not the same line item. If your fee schedule treats them as one D2740, you are subsidizing the anterior cases with the posterior ones and losing margin on both.
2. Chair time per unit, measured at the operatory.Not the textbook number. The number your assistants actually log. A prep-and-scan appointment that runs 55 minutes on average means the D2740 has to support 55 minutes of chair cost, not 40.
3. Remake rate, by lab and by indication.A 6% remake rate on anterior cases is not the same problem as a 6% remake rate on posterior monolithic units. The first signals a shade-communication or impression workflow gap. The second signals a fit-and-occlusion problem that gets baked into your fee whether you account for it or not.

When those three numbers are on the same page, the fee schedule writes itself. When they are not, you are guessing.

How Material Selection Changes the Math

A modern crown-and-bridge fee schedule has to recognize that the lab side has fragmented. The single D2740 code covers monolithic zirconia, layered zirconia, lithium disilicate (pressed or milled), and feldspathic-stacked porcelain on a zirconia substructure. Lab cost across those options can range from roughly $85 to $310 per unit depending on the material, the lab, and the case complexity. That is a 3.6x spread inside a single code.

If your fee for D2740 is $1,450 and your blended lab cost across all materials averages $165, your lab-cost-to-fee ratio is about 11.4%. That looks healthy. But if 30% of your anterior cases are running on layered lithium disilicate at $275 lab cost and chair time at 70 minutes, those specific cases are running at 19% lab cost and a noticeably worse hourly yield.

The practical move is to either (a) split material tiers internally and route patients to the right material based on indication, or (b) accept that anterior cases run a different margin and price the consultation and case-planning fee accordingly. Both are valid. Neither happens if the practice does not have visibility into the lab invoice at the material level.

Ask your lab for a 12-month invoice export, broken out by material code. If the lab cannot produce that in under 48 hours, that is its own data point. At Dani Dental, every account gets a quarterly material-mix report as a standard deliverable, because that is the input the practice needs to run a real fee review.

Remake Rate Is a Fee Schedule Line Item

Most practices treat remakes as a service issue. They are. They are also a fee schedule issue.

If your remake rate on D2740 is 5%, and the average remake costs you 35 minutes of chair time plus a $40 temporary plus the patient-relationship friction, the loaded cost of that 5% is roughly $58 per crown across the whole schedule. If your fee is $1,450, that is a 4% drag on the realized fee. Most practices never book that drag against the code; it sits in the operations budget as lost time.

The two ways to handle this in a fee schedule review:

• Build the expected remake cost into the fee. This is the path most practices end up on by default. It works, but it punishes the patients whose cases seat first time.
• Drive the remake rate down at the lab level so the loaded cost approaches zero. Industry-published remake rates for general C&B work cluster between 3% and 8% depending on the lab and the case mix. Ask any lab how it measures remakes and how it handles the ones that happen.

The second path protects the fee and the patient experience. The first one is the path of least resistance. Pick deliberately.

When to Revisit the Schedule

The traditional cadence is every three years. That cadence was set when material costs, lab costs, and chair-time inputs were stable. None of those are stable right now. Zirconia raw material pricing has moved meaningfully in the last 24 months. Implant restorative components have repriced. Labor at the operatory has repriced faster than that.

A more honest cadence is annually for material-cost-driven codes (the C&B range, the implant restorative range, the removable range), and every two years for everything else. The annual review does not have to be a full rebuild. It has to be a comparison of:

• Last 12 months of lab invoices, by material
• Last 12 months of remake log, by indication
• Last 12 months of chair time per unit, by operator
• Current fee versus current loaded cost

If the loaded cost has moved more than 8% on any code, that code gets a fee adjustment. If it has not, leave it alone and revisit next year.

What to Ask Your Lab Before the Next Review

Three questions:

1. What is my 12-month material mix on C&B cases, by code and by material?
2. What is my 90-day rolling remake rate, broken out by anterior versus posterior?
3. What is your published turnaround time for each material category, and what was my actual average turnaround over the last 90 days?

If the lab cannot answer those three questions on the same call, you do not have enough data to run a real fee schedule review. That is not a peer comparison or a sales pitch. It is the floor.

The practices that get fee schedule strategy right treat the lab as a data partner, not a vendor. The ones that treat the lab as a commodity end up resetting their schedule against a regional median every few years and wondering why the C&B margin keeps drifting.